Galmed Pharmaceuticals Ltd. (GLMD) Shares Up 28.6%
Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) was up 28.6% during trading on Tuesday . The stock traded as high as $5.39 and last traded at $4.72, with a volume of 556,505 shares traded. The stock had previously closed at $3.67.
Several equities research analysts have commented on GLMD shares. Zacks Investment Research upgraded Galmed Pharmaceuticals from a “hold” rating to a “buy” rating and set a $4.75 price objective on the stock in a research report on Monday, July 18th. Roth Capital restated a “buy” rating and issued a $6.00 price objective on shares of Galmed Pharmaceuticals in a research report on Wednesday, July 6th. HC Wainwright restated a “buy” rating on shares of Galmed Pharmaceuticals in a research report on Thursday, June 30th. Maxim Group restated a “buy” rating on shares of Galmed Pharmaceuticals in a research report on Wednesday, June 8th. Finally, FBR & Co set a $20.00 price objective on Galmed Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, August 5th. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. The company has a consensus rating of “Buy” and an average price target of $12.35.
The firm’s market cap is $51.40 million. The stock’s 50-day moving average price is $3.94 and its 200 day moving average price is $4.68.
Galmed Pharmaceuticals (NASDAQ:GLMD) last posted its earnings results on Wednesday, August 3rd. The biopharmaceutical company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.35) by $0.04. Equities research analysts expect that Galmed Pharmaceuticals Ltd. will post ($1.51) earnings per share for the current fiscal year.
About Galmed Pharmaceuticals
Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol.
Receive News & Ratings for Galmed Pharmaceuticals Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.